| abstract |
FIELD: biotechnology.SUBSTANCE: present invention relates to new antibodies able to bind to antigen CD123 (α-receptor of interleukin 3 or IL-3Rα), and can be used in medicine. Invention also enables to obtain immunostimulating conjugates based on antibodies to CD123 and various anticancer agents. In addition, the invention can be used for diagnosing and treating those types of cancer, cells of which there is increased expression of CD123 antigen, e.g. acute myeloid leukemia, lymphoblastic or lymphocytic leukemia or other malignant B-cell tumors.EFFECT: disclosed are anti-CD123 antibodies and conjugates and derivatives thereof.59 cl, 30 ex, 11 tbl, 33 dwg |